CAESAREA, Israel--(BUSINESS WIRE)--Based upon adherence to the strictest international standards of quality and clinical trials proving the EndoPAT’s safety and efficacy, the Japanese government has granted SHONIN (“clearance”) to Itamar-Medical’s EndoPAT, paving the way to widespread use in Japan for diagnosing endothelial dysfunction, a key cause of cardiovascular disease.
